These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27998692)

  • 1. Squill Oxymel, a traditional formulation from Drimia Maritima (L.) Stearn, as an add-on treatment in patients with moderate to severe persistent asthma: A pilot, triple-blind, randomized clinical trial.
    Nejatbakhsh F; Karegar-Borzi H; Amin G; Eslaminejad A; Hosseini M; Bozorgi M; Gharabaghi MA
    J Ethnopharmacol; 2017 Jan; 196():186-192. PubMed ID: 27998692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Add-On Treatment for Moderate COPD with Squill-Oxymel (a Traditional Formulation from
    Mohammadi-Araghi M; Eslaminejad A; Karegar-Borzi H; Mazloomzadeh S; Nejatbakhsh F
    Evid Based Complement Alternat Med; 2022; 2022():5024792. PubMed ID: 35677368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Aspects of Squill; An Evidence-Based Review.
    Saket K; Afshari JT; Saburi E; Yousefi M; Salari R
    Curr Drug Discov Technol; 2020; 17(3):318-324. PubMed ID: 30686259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, open labeled, comparative study to assess the efficacy and safety of controller medications as add on to inhaled corticosteroid and long-acting β2 agonist in the treatment of moderate-to-severe persistent asthma.
    Patel YA; Patel P; Bavadia H; Dave J; Tripathi CB
    J Postgrad Med; 2010; 56(4):270-4. PubMed ID: 20935397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Montelukast improves air trapping, not airway remodeling, in patients with moderate-to-severe asthma: a pilot study.
    Gao JM; Cai F; Peng M; Ma Y; Wang B
    Chin Med J (Engl); 2013 Jun; 126(12):2229-34. PubMed ID: 23786930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma.
    Ohta K; Miyamoto T; Amagasaki T; Yamamoto M;
    Respirology; 2009 Nov; 14(8):1156-65. PubMed ID: 19909462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
    Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
    Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic effects of inhaled long-acting beta2-adrenergics (LABA) and corticosteroids (ICS) are not affected by their inhalation sequence in moderate/persistent asthma.
    Dal Negro RW; Micheletto C; Tognella S; Trevisan F; Guerriero M
    Eur Ann Allergy Clin Immunol; 2006 May; 38(5):153-7. PubMed ID: 17058847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the effects of zafirlukast 40 mg b.i.d. in addition to preexisting therapy of high-dose inhaled steroids on symptomatic patients with reversible respiratory obstruction: preliminary data.
    Centanni S; Santus P; Casanova F; Di Marco F; Brazzola G; Canonica GW
    Drugs Exp Clin Res; 2000; 26(4):133-8. PubMed ID: 11109513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 12-week, multicenter, randomized, partially blinded, active-controlled, parallel-group study of budesonide inhalation suspension in adolescents and adults with moderate to severe persistent asthma previously receiving inhaled corticosteroids with a metered-dose or dry powder inhaler.
    Murphy K; Noonan M; Silkoff PE; Uryniak T
    Clin Ther; 2007 Jun; 29(6):1013-26. PubMed ID: 17692718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Equivalent efficacy and safety of a new HFA-134a formulation of BDP compared with the conventional CFC in adult asthmatics.
    Anderson PB; Langley SJ; Mooney P; Jones J; Addlestone R; Rossetti A; Cantini L
    J Investig Allergol Clin Immunol; 2002; 12(2):107-13. PubMed ID: 12371526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250 microg/Salmeterol 50 microg.
    Gelb AF; Taylor CF; Simmons M; Shinar C
    Pulm Pharmacol Ther; 2009 Dec; 22(6):516-21. PubMed ID: 19467341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
    Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP
    Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma.
    Molfino NA; Kuna P; Leff JA; Oh CK; Singh D; Chernow M; Sutton B; Yarranton G
    BMJ Open; 2016 Jan; 6(1):e007709. PubMed ID: 26739717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced medication use and improved pulmonary function with supplements containing vegetable and fruit concentrate, fish oil and probiotics in asthmatic school children: a randomised controlled trial.
    Lee SC; Yang YH; Chuang SY; Huang SY; Pan WH
    Br J Nutr; 2013 Jul; 110(1):145-55. PubMed ID: 23211647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial.
    Papi A; Corradi M; Pigeon-Francisco C; Baronio R; Siergiejko Z; Petruzzelli S; Fabbri LM; Rabe KF
    Lancet Respir Med; 2013 Mar; 1(1):23-31. PubMed ID: 24321801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily evening administration of mometasone furoate in asthma treatment initiation.
    Bensch GW; Prenner B; Berkowitz R; Galant S; Ramsdell J; Lutsky B
    Ann Allergy Asthma Immunol; 2006 Apr; 96(4):533-40. PubMed ID: 16680923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials.
    Kerstjens HA; Casale TB; Bleecker ER; Meltzer EO; Pizzichini E; Schmidt O; Engel M; Bour L; Verkleij CB; Moroni-Zentgraf P; Bateman ED
    Lancet Respir Med; 2015 May; 3(5):367-76. PubMed ID: 25682232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 12-week, randomized, parallel-group, proof-of-concept study of tulobuterol patch and salmeterol inhaler as add-on therapy in adult-onset mild-to-moderate asthma.
    Inoue H; Niimi A; Matsumoto H; Ito I; Oguma T; Otsuka K; Takeda T; Nakaji H; Tajiri T; Iwata T; Nagasaki T; Mishima M
    Clin Exp Pharmacol Physiol; 2017 Jan; 44(1):21-29. PubMed ID: 27718262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.